To access this element change to forms mode OFF
Grant Award View - GA52676
Targeting alternative SMAD-related suppressive signalling pathway...
GA ID:
GA52676
Agency:
Cancer Australia
Approval Date:
7-May-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
2-Sep-2019 to 1-Sep-2021
Value (AUD):
$34,482.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Targeting alternative SMAD-related suppressive signalling pathway enhance NK cell response
Purpose:
This project will determine if alternative decapentaplegic homolog (SMAD)-related immune suppressive pathway produced in tumours can be neutralised in synergism with BRAFV600E inhibition to allow tumour resident NK cells to maintain their conventional tumour immune functions and prevent cancer spread. It is a completely novel approach and this information will allow for the more rational design of melanoma treatments that targets NK cells following surgery and local radiotherapy and/or chemotherapy.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The University of Queensland
Recipient ABN:
63 942 912 684
Grant Recipient Location
Suburb:
St Lucia
Town/City:
Brisbane
Postcode:
4072
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA